- $31.36m
- $24.46m
- $7.53m
Evaxion Biotech A/S expected to post a loss of 19 cents a share - Earnings Preview
Brief: Evaxion Announces Encouraging Initial Phase 2 Clinical Data On Its Personalized Cancer Vaccine EVX-01
U.S. STOCKS ON THE MOVE-Gold miners, Goosehead Insurance, FedEx
U.S. STOCKS ON THE MOVE-Lululemon, Copper miners, Gold miners
Evaxion soars on collaboration with Afrigen for gonorrhea vaccine
Evaxion Biotech A/S expected to post a loss of 21 cents a share - Earnings Preview
Brief: Evaxion Announces Financing Commitments Totaling Up To USD 20 Million With Negma Group
Brief: Evaxion Biotech Says EVX-B1 Immunization Resulted In Complete Bacterial Clearance Of Staphylococcus Aureus In Multiple Organs
U.S. STOCKS ON THE MOVE-Spotify, Akero Therapeutics, Cyxtera Technologies
U.S. STOCKS ON THE MOVE-Tesla, Moderna, Oil tanker firms
Cancer drugmakers rise as industry meet fuels investor interest (updated)
U.S. STOCKS ON THE MOVE-Foghorn Therapeutics, Novavax, Apple
Cancer drugmakers rise as industry meet fuels investor interest
Cancer drug developers up on presenting promising data from studies
Brief: Evaxion’S Ai Technology Identifies Cancer Vaccine Targets Associated With Longer Progression-Free Survival Of Melanoma Patients
Brief: Evaxion Announces Business Update And First Quarter 2023 Financial Results
Brief: Evaxion Biotech A/S Positive Clinical Response As Demonstrated In 8 Out Of 12 Patients Receiving Evx-01 In Combination With A Checkpoint Inhibitor
Brief: Evaxion Announces Promising Clinical Phase 1 Data For Its Personalized Cancer Vaccine Evx-01
Brief: Evaxion Biotech Reports Fourth Quarter And Full Year 2022 Financial Results And Business Update